- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Zevra Therapeutics Inc (ZVRA)
The Zevra Therapeutics share price today is 11.870, view NASDAQ ZVRA stock exchange data. Track the latest Zevra Therapeutics share price with real-time updates on ZVRA stock performance including market cap, day range, 52-week range and dividend yield. Access ZVRA charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.750
12.010
52 wk Range
7.160
15.035
ZVRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.75012.010
52 wk Range
7.16015.035
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ZVRA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
25.000
Upside
+110.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.000
(+110.61% Upside)
Zevra Therapeutics Inc SWOT Analysis
MIPLYFFA's Triumph | Zevra's flagship drug exceeds expectations with $17.1M Q1 sales, driving analyst projections to $80M for 2025 and $117M for 2026 |
Financial Fortitude | Explore Zevra's robust $217M cash position, extending runway to 2029 and fueling strategic growth initiatives in the rare disease market |
Pipeline Potential | Delve into Zevra's diverse portfolio, including OLPRUVA's growth strategies and the promising Phase 3 trial of celiprolol for VEDS |
Global Ambitions | Learn about Zevra's European expansion plans for MIPLYFFA, with regulatory submission slated for late 2025 and encouraging data from French EAP |
Zevra Therapeutics Inc Earnings Call Summary for Q2/2026
- Zevra reported Q2 2026 EPS of $0.14 and revenue of $39.7M, beating estimates of $0.11 and $34.17M; revenue rose 53% year-over-year.
- MIPLYFFA U.S. sales reached $30.2M, up 40% annually, accounting for 76% of total revenue; company ended quarter with $260.2M cash.
- Operating expenses fell 13% to $21M; net income was $8.8M versus $74.7M prior year, which included large non-cash gain.
- Company awaits Q4 2026 CHMP re-examination opinion for European MIPLYFFA approval after initial negative decision.
- Management expects continued MIPLYFFA growth through expanded diagnosis efforts; celiprolol Phase III trial enrolled 66 of 150 target patients.
Last Updated: 06-08-2026, 03:02 am
Read Full TranscriptEarnings
Latest Release
05-08-2026
EPS / Forecast
0.14 / 0.11
Revenue / Forecast
39.7M / 34.17M
Compare ZVRA to Peers and Sector
Metrics to compare | ZVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZVRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.3x | −2.3x | −0.4x | |
PEG Ratio | 0.01 | −0.35 | 0.00 | |
Price/Book | 3.2x | 0.8x | 2.6x | |
Price / LTM Sales | 5.2x | 1.8x | 3.1x | |
Upside (Analyst Target) | 102.2% | 78.8% | 48.6% | |
Fair Value Upside | Unlock | 14.0% | 5.8% | Unlock |
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Zevra Therapeutics (ZVRA) Share Price Today?
The Zevra Therapeutics share price today is 11.870.
What is the current Zevra Therapeutics (ZVRA) share price and day range?
As of 24-08-2026, the Zevra Therapeutics share price is 11.870, with a previous close of 11.870. The share price has ranged from 11.750 to 12.010 today, while the 52-week range spans from 7.160 to 15.035.
What Is the Zevra Therapeutics Market Cap?
As of today, Zevra Therapeutics market cap is 704.890M.
What Is the Zevra Therapeutics (ZVRA) Share Price Target?
The average 12-month share price target for Zevra Therapeutics is 25.000, with a high estimate of 35 and a low estimate of 20. 9 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +110.61% Upside potential.
What Is Zevra Therapeutics's Earnings Per Share (TTM)?
The Zevra Therapeutics EPS (TTM) is 0.960.
When Is the Next Zevra Therapeutics Earnings Date?
Zevra Therapeutics will release its next earnings report on 11-11-2026.
From a Technical Analysis Perspective, Is ZVRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Zevra Therapeutics Trade On?
Zevra Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Zevra Therapeutics?
The stock symbol for Zevra Therapeutics is "ZVRA."
How Many Times Has Zevra Therapeutics Stock Split?
Zevra Therapeutics has split 1 times.
How Many Employees Does Zevra Therapeutics Have?
Zevra Therapeutics has 61 employees.
What Is the ZVRA After Hours Price?
ZVRA's last after hours stock price is 11.841, the stock has changed by -0.029, or -0.240%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.